表紙:癌バイオマーカー市場の動向分析・競合市場シェア・予測 (2016-2026年) :タイプ (タンパク質バイオマーカー・遺伝子バイオマーカー)・癌タイプ・プロファイリング技術・用途・地域別
市場調査レポート
商品コード
948274

癌バイオマーカー市場の動向分析・競合市場シェア・予測 (2016-2026年) :タイプ (タンパク質バイオマーカー・遺伝子バイオマーカー)・癌タイプ・プロファイリング技術・用途・地域別

Cancer Biomarkers Market Size, By Type (Protein Biomarker, Genetic Biomarker, and Others ), By Cancer Type, By Profiling Technology, By Application, and By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26

出版日: | 発行: Blueweave Consulting & Research Private Limited | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.86円
癌バイオマーカー市場の動向分析・競合市場シェア・予測 (2016-2026年) :タイプ (タンパク質バイオマーカー・遺伝子バイオマーカー)・癌タイプ・プロファイリング技術・用途・地域別
出版日: 2020年03月01日
発行: Blueweave Consulting & Research Private Limited
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の癌バイオマーカー市場規模は、2019年に130億6500万米ドルとなり、2026年までに294億5000万米ドルへ達すると予測され、2020年から2026年の予測期間中、12.61%のCAGRで成長すると予測されています。癌のいくつかの病期におけるバイオマーカーの使用についての認識の高まりは、市場成長を促進しています。 サロゲートエンドポイントおよび薬物標的開発におけるバイオマーカーの利用の急増、癌診断の研究に関わる研究者&学生における関心の高まり、および癌研究におけるバイオマーカーの必要性は、癌バイオマーカー市場の成長にとって重要な成功要因の一部となっています。

当レポートでは、世界の癌バイオマーカー市場について調査し、現在の市場動向、市場への影響要因、各セグメント・地域別による市場の分析と予測、および主要企業のプロファイルなどを提供しています。

第1章 調査フレームワーク

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の癌バイオマーカー分析

  • DROC分析
    • 成長要因
    • 抑制要因
    • 市場機会
    • 課題
  • 技術情勢
  • 規制の枠組み
  • 企業の市場シェア分析
  • ポーターのファイブフォース分析

第5章 世界の癌バイオマーカー市場概要

  • 市場推計・予測:金額ベース
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
      • タンパク質バイオマーカー
      • 遺伝的バイオマーカー
      • その他(細胞、ウイルス、および炭水化物バイオマーカー)
    • 癌タイプ別
      • 乳癌
      • 肺癌
      • 大腸癌
      • 前立腺癌
      • 甲状腺癌
      • 膀胱癌
      • 腎臓癌
      • その他
    • プロファイリング技術
      • オミクス技術
      • イメージング技術
      • 免疫測定法
      • 細胞遺伝学
      • バイオインフォマティクス
      • その他
    • アプリケーション別
      • 診断
      • 創薬&開発
      • 予後
      • リスクアセスメント
      • その他
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • ラテンアメリカ
      • 中東・アフリカ

第6章 北米の癌バイオマーカー市場

  • 市場推計・予測:金額ベース
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
    • 癌タイプ別
    • プロファイリング技術別
    • アプリケーション別
    • 国別
      • 米国
      • カナダ

第7章 欧州の癌バイオマーカー市場

  • 市場推計・予測:金額ベース
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
    • 癌タイプ別
    • プロファイリング技術別
    • アプリケーション別
    • 国別
      • ドイツ
      • 英国
      • フランス
      • イタリア
      • スペイン
      • その他欧州

第8章 アジア太平洋の癌バイオマーカー市場

  • 市場推計・予測:金額ベース
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
    • 癌タイプ別
    • プロファイリング技術別
    • アプリケーション別
    • 国別
      • 中国
      • インド
      • 日本
      • 韓国
      • アジア太平洋のその他諸国

第9章 ラテンアメリカの癌バイオマーカー市場

  • 市場推計・予測:金額ベース
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
    • 癌タイプ別
    • プロファイリング技術別
    • アプリケーション別
    • 国別
      • ブラジル
      • メキシコ
      • アルゼンチン
      • その他ラテンアメリカ

第10章 中東およびアフリカの癌バイオマーカー市場

  • 市場推計・予測:金額ベース
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
    • 癌タイプ別
    • プロファイリング技術別
    • アプリケーション別
    • 国別
      • サウジアラビア
      • アラブ首長国連邦
      • 南アフリカ
      • その他の中東・アフリカ

第11章 企業プロファイル (会社概要、財務マトリックス、製品情勢、主要人物、主要競合企業、連絡先住所、および戦略的展望)

  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Roche Diagnostics
  • Qiagen N.V.
  • Illumina
  • G.E. Healthcare
  • Agilent Technologies
  • Biomerieux SA
  • Merck & Co.
  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Danaher Corporation
  • Myriad Genetics
  • Sysmex Corporation
  • Hologic
  • Quest Diagnostics
  • その他の有望企業
目次
Product Code: BWC19432

Title:
Cancer Biomarkers Market Size, By Type (Protein Biomarker, Genetic Biomarker, and Others (cell, viral, and carbohydrate biomarkers)), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Bladder Cancer, Kidney Cancer, and Others), By Profiling Technology (Omics Technologies, Imaging Technologies, Bioinformatics, Immunoassays, Cytogenetics, and Others), By Application (Diagnostics, Drug Discovery & Development, Prognostics, Risk Assessment, and Others), and By Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America); Trend Analysis, Competitive Market Share & Forecast, 2016-26.

According to BlueWeave Consulting, the Global Cancer Biomarkers market has reached USD 13.065 Billion in 2019 and estimated to reach USD 29.45 Billion in 2026, at a CAGR of 12.61% during the forecast period 2020-2026. Rising awareness about the usage of biomarkers at several stages of cancer pushing the market upward.

In addition, lack of physical activities, frequent sun & UV exposure, improper diet, and growing consumption of tobacco are some of the essential factors that have attributed to the escalating prevalence of cancer. Around 22% of cancer deaths are caused due to tobacco consumption and are regarded as the principal risk factor for cancer. Moreover, the growing demand for clinical diagnosis in cancer's early stages and geriatric population base further propels the usage rates of cancer biomarkers. Besides, few internal factors such as hormonal imbalance, genetic mutation, and metabolic mutation contribute towards the surge in cancer cases, which in turn boosts the demand for cancer biomarkers.

Surging utilization of the biomarkers in surrogate endpoints & drug targets developments, increasing interest among researchers & students regarding cancer diagnostic researchers, and need for the biomarkers in cancer research are few crucial success factors for the growth of the global cancer biomarkers market. Most epidemiological studies use biomarkers to examine various stages of human disease. It requires careful handling and storage of sensitive biological samples to obtain a great deal of information from small samples and reduce future research costs by using banked samples.

The genetic biomarker segment in Type is expected to grow at a very high CAGR during the forecast horizon

Based on Type, the genetic biomarker segment is forecasted to dominate during the forecast period, owing to the advancement of technologies to detect the mutation. Gene expression profiling (microarray), Next-generation sequencing (NGS), and polymerase chain reaction (PCR) are the essential technologies used for genetic biomarker discovery and diagnosis. Advancements in high-throughput technologies are the major factors driving the cancer biomarkers market.

Technological advancements

There have been significant technological developments over fields such as diagnostic imaging, immunoassays, omics technologies, and bioinformatics. Using advanced bioinformatics tools, developments in omics technology allow faster acquisition of proteomic, genomic, and metabolomics data and its alliance with clinical trial data. Over the past decade, the omics movement has growing biomarker applications in biomedical research. Additionally, developments in high-throughput genomic technologies facilitate the identification and analysis of key gene mutations and polymorphisms, thereby expanding the spectrum of available genomic biomarkers.

Increased incidence and prevalence of different types of cancer

There is a surge in the cases of cancer among the global population, which has boosted the demand for Cancer Biomarkers. As per the World Health Organization, it is anticipated to increase cancer cases over the next two decades further. Cancer is prevalent largely in lower and middle-income nations since they lack suitable healthcare infrastructure to combat the condition effectively. In addition, the cancer cases were higher in men than in women.

North America is expected to have the lion's share in the global Cancer Biomarkers market during the anticipated period.

By geography, the global Cancer Biomarkers Market segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is expected to have the lion's share in the global cancer biomarkers market during the forecast period, owing to the adoption of advanced technologies, increasing the number of research studies for the development of novel biomarkers. The existence of a large number of pharmaceutical firms, rising funding and investments from public and private organizations, and the growing use of biomarkers in patient stratification and drug development method.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary Research Respondents
  • 2.5. Market Size Estimation
  • 2.6. Assumption for The Study
  • 2.7. Market Breakdown & Data Triangulation

3. Executive Summary

4. Global Cancer Biomarkers Insights

  • 4.1. DROC Analysis
    • 4.1.1. Growth Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. Technological Landscape
  • 4.3. Regulatory Framework
  • 4.4. Company Market Share Analysis, 2019
  • 4.5. Porter's Five forces analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Intensity of Rivalry

5. Global Cancer Biomarkers Market Overview

  • 5.1. Market Size & Forecast by Value, 2016-2026
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast 2016-2026
    • 5.2.1. By Type
      • 5.2.1.1. Protein Biomarker
      • 5.2.1.2. Genetic Biomarker
      • 5.2.1.3. Others (cell, viral, and carbohydrate biomarkers)
    • 5.2.2. By Cancer Type
      • 5.2.2.1. Breast Cancer
      • 5.2.2.2. Lung Cancer
      • 5.2.2.3. Colorectal Cancer
      • 5.2.2.4. Prostate Cancer
      • 5.2.2.5. Thyroid Cancer
      • 5.2.2.6. Bladder Cancer
      • 5.2.2.7. Kidney Cancer
      • 5.2.2.8. Others
    • 5.2.3. By Profiling Technology
      • 5.2.3.1. Omics Technologies
      • 5.2.3.2. Imaging Technologies
      • 5.2.3.3. Immunoassays
      • 5.2.3.4. Cytogenetics
      • 5.2.3.5. Bioinformatics
      • 5.2.3.6. Others
    • 5.2.4. By Application
      • 5.2.4.1. Diagnostics
      • 5.2.4.2. Drug Discovery & Development
      • 5.2.4.3. Prognostics
      • 5.2.4.4. Risk Assessment
      • 5.2.4.5. Others
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia Pacific
      • 5.2.5.4. Latin America
      • 5.2.5.5. Middle East & Africa

6. North America Cancer Biomarkers Market

  • 6.1. Market Size & Forecast by Value, 2016-2026
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast 2016-2026
    • 6.2.1. By Type
    • 6.2.2. By Cancer Type
    • 6.2.3. By Profiling Technology
    • 6.2.4. By Application
    • 6.2.5. By Country
      • 6.2.5.1. U.S
      • 6.2.5.2. Canada

7. Europe Cancer Biomarkers Market

  • 7.1. Market Size & Forecast by Value, 2016-2026
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast 2016-2026
    • 7.2.1. By Type
    • 7.2.2. By Cancer Type
    • 7.2.3. By Profiling Technology
    • 7.2.4. By Application
    • 7.2.5. By Country
      • 7.2.5.1. Germany
      • 7.2.5.2. U.K
      • 7.2.5.3. France
      • 7.2.5.4. Italy
      • 7.2.5.5. Rest of Europe

8. Asia Pacific Cancer Biomarkers Market

  • 8.1. Market Size & Forecast by Value, 2016-2026
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast 2016-2026
    • 8.2.1. By Type
    • 8.2.2. By Cancer Type
    • 8.2.3. By Profiling Technology
    • 8.2.4. By Application
    • 8.2.5. By Country
      • 8.2.5.1. China
      • 8.2.5.2. India
      • 8.2.5.3. Japan
      • 8.2.5.4. South Korea
      • 8.2.5.5. Rest of Asia Pacific

9. Latin America Cancer Biomarkers Market

  • 9.1. Market Size & Forecast by Value, 2016-2026
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast 2016-2026
    • 9.2.1. By Type
    • 9.2.2. By Cancer Type
    • 9.2.3. By Profiling Technology
    • 9.2.4. By Application
    • 9.2.5. By Country
      • 9.2.5.1. Brazil
      • 9.2.5.2. Mexico
      • 9.2.5.3. Argentina
      • 9.2.5.4. Rest of Latin America

10.Middle East & Africa Cancer Biomarkers Market

  • 10.1. Market Size & Forecast by Value, 2016-2026
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast 2016-2026
    • 10.2.1. By Type
    • 10.2.2. By Cancer Type
    • 10.2.3. By Profiling Technology
    • 10.2.4. By Application
    • 10.2.5. By Country
      • 10.2.5.1. Saudi Arabia
      • 10.2.5.2. UAE
      • 10.2.5.3. South Africa
      • 10.2.5.4. Rest of Middle East & Africa

11.Company Profile (Company Overview, Financial Matrix, Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 11.1. Thermo Fisher Scientific
  • 11.2. Bio-Rad Laboratories
  • 11.3. Roche Diagnostics
  • 11.4. Qiagen N.V.
  • 11.5. Illumina
  • 11.6. G.E. Healthcare
  • 11.7. Agilent Technologies
  • 11.8. Biomerieux SA
  • 11.9. Merck & Co.
  • 11.10. Abbott Laboratories
  • 11.11. Becton, Dickinson, and Company
  • 11.12. Danaher Corporation
  • 11.13. Myriad Genetics
  • 11.14. Sysmex Corporation
  • 11.15. Hologic
  • 11.16. Quest Diagnostics
  • 11.17. Other Prominent Players

List of Figures

Fig: Global Cancer Biomarkers Segmentation

Fig: Company Market Share Analysis, 2019

Fig: Global Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Region, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: North America Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: North America Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Europe Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Europe Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Latin America Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Latin America Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Middle East & Africa Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

List of Tables:

Table: Global Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Region, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Middle East & Africa Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Thermo Fisher Scientific Financial Analysis

Table: Bio-Rad Laboratories Financial Analysis

Table: Roche Diagnostics Financial Analysis

Table: Qiagen N.V. Financial Analysis

Table: G.E. Healthcare Financial Analysis

Table: Agilent Technologies Financial Analysis

Table: Biomerieux SA Financial Analysis

Table: Merck & Co. Financial Analysis

Table: Abbott Laboratories Financial Analysis

Table: Danaher Corporation Financial Analysis